During this phase, insulin sensitivity declines 515% independent of age alone, accelerating weight gain and metabolic dysfunction
Results: The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 6.6% of patients in the semaglutide group and 8.9% in the placebo group, indicating a 26% lower risk with semaglutide
[,] GLP-1 receptor agonists are currently classified as Food and Drug Administration (FDA) pregnancy category C, indicating that while animal studies have shown adverse fetal effects, adequate and well-controlled studies in pregnant women are deficient, and these agents are not recommended for use during pregnancy
Whole grain consumption trends and associations with body weight measures in the United States: results from the cross-sectional national health and nutrition examination survey 2001-2012
Does AOD-9604 affect blood sugar levels